Monovoxel 1H magnetic resonance spectroscopy in the progression of gliomas.
OBJECTIVE
Can monovoxel magnetic resonance spectroscopy (MRS) reliably follow tumour progression in low-grade glioma?


METHODS
21 patients with low-grade glioma underwent at least 3 MRS.


RESULTS
For progression from a grade II to grade III tumour, a sensitivity of 57.1% and specificity of 60% were observed, with a positive predictive value (PPV) of 48.8% and a negative predictive value (NPV) of 54.5%. For progression under treatment, we obtained a sensitivity of 57.1% by N-acetylaspartate (NAA)/choline (Cho) and myoinositol/creatine (Cr) and a specificity of 100% by Cho/Cr and lipids, with a PPV of 80% and a NPV of 63.6%.


CONCLUSIONS
We found that NAA/Cho is the best marker of tumour progression before therapy, with a sensitivity of 53.9%. For the therapeutic response, sensitivity was only 28.2%.
Alimenti
Alessandro
A
Department of Radiology, Geneva University Hospital, Geneva, Switzerland.
Delavelle
Jacqueline
J
Lazeyras
François
F
Yilmaz
Hasan
H
Dietrich
Pierre-Yves
PY
de Tribolet
Nicolas
N
Lövblad
Karl-Olof
KO
D000328:Adult; D000368:Aged; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis*; D002794:Choline / Q000378:metabolism; D003401:Creatine / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D005910:Glioma / Q000175:diagnosis*; D006801:Humans; D007294:Inositol / Q000378:metabolism; D008137:Longitudinal Studies; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011522:Protons; D012189:Retrospective Studies